About Heska (NASDAQ:HSKA)
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. The company sells its products to veterinarians through a field organization, a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSKA
CUSIPN/A
Phone970-493-7272
Debt
Debt-to-Equity RatioN/A
Current Ratio2.45%
Quick Ratio1.18%
Price-To-Earnings
Trailing P/E Ratio38.20
Forward P/E Ratio41.56
P/E Growth2.2
Sales & Book Value
Annual Sales$129.34 million
Price / Sales4.66
Cash Flow$2.9005 per share
Price / Cash27.94
Book Value$13.87 per share
Price / Book5.84
Profitability
EPS (Most Recent Fiscal Year)$2.07
Net Income$9.95 million
Net Margins7.53%
Return on Equity16.23%
Return on Assets11.93%
Miscellaneous
Employees345
Outstanding Shares7,430,000
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Wednesday, February, 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.07. The medical research company earned $36.04 million during the quarter, compared to analysts' expectations of $40.56 million. Heska had a net margin of 7.53% and a return on equity of 16.23%. The business's revenue was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.46 EPS. View Heska's Earnings History.
When is Heska's next earnings date?
What price target have analysts set for HSKA?
6 Wall Street analysts have issued 12 month price objectives for Heska's shares. Their forecasts range from $77.00 to $129.50. On average, they expect Heska's share price to reach $103.10 in the next twelve months. View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (1/3/2018)
- 2. B. Riley analysts commented, "We expect Q3 results to be generally in line. We forecast revenue of $35.8 million and EPS of $0.40 versus consensus of $36.0 million and EPS of $0.41. We model revenue growth at 7.1%, reflecting ongoing momentum in core blood diagnostics within its Core Companion Animal Health offset by Other Vaccines, Pharmaceuticals and Products segment which pulled forward revenue last quarter (but expecting to finish off Q4 strong)." (10/27/2017)
Who are some of Heska's key competitors?
Some companies that are related to Heska include Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Mesoblast (MESO), EntreMed (CASI), BioCryst Pharmaceuticals (BCRX), PDL Biopharma (PDLI), Vericel (VCEL), Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA) and Solid Biosciences (SLDB).
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Mr. Kevin S. Wilson, CEO, Pres & Director (Age 46)
- Mr. Jason A. Napolitano, COO, Chief Strategist & Sec. (Age 50)
- Mr. Steven M. Eyl, Exec. VP of Global Sales & Marketing (Age 52)
- Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 55)
- Dr. Michael J. McGinley, Pres of Biologicals & Pharmaceuticals (Age 57)
Has Heska been receiving favorable news coverage?
News stories about HSKA stock have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Heska earned a media sentiment score of 0.10 on Accern's scale. They also assigned media stories about the medical research company an impact score of 45.14 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $81.04.
How big of a company is Heska?
Heska has a market capitalization of $590.19 million and generates $129.34 million in revenue each year. The medical research company earns $9.95 million in net income (profit) each year or $2.07 on an earnings per share basis. Heska employs 345 workers across the globe.
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (HSKA)
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Heska (NASDAQ:HSKA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Heska in the last 12 months. Their average twelve-month price target is $103.10, suggesting that the stock has a possible upside of 27.22%. The high price target for HSKA is $129.50 and the low price target for HSKA is $77.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.67 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $103.10 | $103.10 | $114.3750 | $106.40 |
| Price Target Upside: | 27.22% upside | 51.66% upside | 39.96% upside | 16.44% upside |
Heska (NASDAQ:HSKA) Consensus Price Target History
Heska (NASDAQ:HSKA) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Heska (NASDAQ:HSKA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Heska (NASDAQ HSKA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 86.33%
Heska (NASDAQ HSKA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/29/2017 | Michael J Mcginley | Insider | Sell | 7,826 | $87.14 | $681,957.64 | 106,771 |  |
| 11/27/2017 | Michael J Mcginley | Insider | Sell | 1 | $88.54 | $88.54 | 106,771 | |
| 8/31/2017 | Nancy Wisnewski | EVP | Sell | 825 | $102.21 | $84,323.25 | 38,114 | |
| 8/30/2017 | John Mcmahon | CFO | Sell | 2,608 | $101.17 | $263,851.36 | 193 | |
| 6/1/2017 | Steve Asakowicz | EVP | Sell | 382 | $100.08 | $38,230.56 | 10,382 | |
| 5/31/2017 | Michael J Mcginley | Insider | Sell | 11,189 | $98.53 | $1,102,452.17 | 111,877 | |
| 5/31/2017 | Rod Lippincott | EVP | Sell | 11,227 | $98.00 | $1,100,246.00 | 11,292 | |
| 5/24/2017 | Jason A. Napolitano | COO | Sell | 5,000 | $100.50 | $502,500.00 | | |
| 5/24/2017 | Nancy Wisnewski | EVP | Sell | 250 | $100.17 | $25,042.50 | 38,901 | |
| 5/23/2017 | Carol Wrenn | Director | Sell | 1,630 | $96.95 | $158,028.50 | 6,174 | |
| 5/23/2017 | John Mcmahon | CFO | Sell | 587 | $97.00 | $56,939.00 | 295 | |
| 5/4/2017 | Sharon J Larson | Director | Buy | 1,000 | $90.00 | $90,000.00 | 3,294 | |
| 4/11/2017 | Jason A. Napolitano | COO | Sell | 1,100 | $102.98 | $113,278.00 | | |
| 4/10/2017 | Jason A. Napolitano | COO | Sell | 3,900 | $102.94 | $401,466.00 | | |
| 3/9/2017 | John Mcmahon | CFO | Sell | 708 | $97.42 | $68,973.36 | 200 | |
| 3/9/2017 | Rod Lippincott | EVP | Sell | 5,157 | $97.87 | $504,715.59 | 10,513 | |
| 3/6/2017 | Kevin S Wilson | CEO | Sell | 8,000 | $90.00 | $720,000.00 | 110,000 | |
| 1/10/2017 | Jason A. Napolitano | COO | Sell | 5,000 | $74.73 | $373,650.00 | | |
| 11/29/2016 | G Irwin Gordon | Director | Sell | 3,000 | $66.11 | $198,330.00 | 17,596 | |
| 11/28/2016 | John Mcmahon | CFO | Sell | 1,999 | $65.64 | $131,214.36 | 584 | |
| 11/22/2016 | Rod Lippincott | EVP | Sell | 5,000 | $64.85 | $324,250.00 | 10,192 | |
| 9/1/2016 | Jason A. Napolitano | CFO | Sell | 5,000 | $52.53 | $262,650.00 | | |
| 8/29/2016 | Kevin S Wilson | CEO | Sell | 20,000 | $51.80 | $1,036,000.00 | 110,000 | |
| 8/24/2016 | John Mcmahon | VP | Sell | 137 | $51.30 | $7,028.10 | | |
| 8/9/2016 | Steve Asakowicz | EVP | Sell | 4,698 | $52.55 | $246,879.90 | 12,858 | |
| 8/3/2016 | Kevin S Wilson | CEO | Sell | 30,736 | $47.34 | $1,455,042.24 | 140,720 | |
| 7/29/2016 | Kevin S Wilson | CEO | Sell | 20 | $43.95 | $879.00 | 140,736 | |
| 7/20/2016 | Kevin S Wilson | CEO | Sell | 3,779 | $44.02 | $166,351.58 | 140,756 | |
| 7/18/2016 | Kevin S Wilson | CEO | Sell | 5,465 | $44.31 | $242,154.15 | 144,535 | |
| 7/8/2016 | Kevin S Wilson | CEO | Sell | 10,000 | $42.37 | $423,700.00 | 150,000 | |
| 7/7/2016 | Jason A. Napolitano | CFO | Sell | 20,000 | $41.00 | $820,000.00 | | |
| 7/6/2016 | Kevin S Wilson | CEO | Sell | 5,960 | $40.27 | $240,009.20 | 160,000 | |
| 7/1/2016 | Kevin S Wilson | CEO | Sell | 14,040 | $38.94 | $546,717.60 | 165,960 | |
| 6/2/2016 | Kevin S Wilson | CEO | Sell | 20,000 | $36.74 | $734,800.00 | 190,000 | |
| 5/12/2016 | Kevin S Wilson | CEO | Sell | 5,000 | $38.50 | $192,500.00 | 200,000 | |
| 5/10/2016 | Kevin S Wilson | CEO | Sell | 15,000 | $36.75 | $551,250.00 | 210,000 | |
| 5/10/2016 | Michael J Mcginley | Insider | Sell | 5,998 | $36.50 | $218,927.00 | 30,801 | |
| 5/10/2016 | Sharon L Riley | Director | Sell | 5,000 | $36.87 | $184,350.00 | 9,500 | |
| 5/9/2016 | Kevin S Wilson | CEO | Sell | 11,000 | $35.61 | $391,710.00 | 228,718 | |
| 5/5/2016 | Sharon L Riley | Director | Sell | 15,000 | $35.66 | $534,900.00 | 9,500 | |
| 5/3/2016 | Jason A Napolitano | CFO | Sell | 5,000 | $35.75 | $178,750.00 | 63,544 | |
| 3/8/2016 | Sharon L Riley | Director | Buy | 1,000 | $32.49 | $32,490.00 | 5,500 | |
| 1/27/2016 | Jason A Napolitano | CFO | Sell | 15,000 | $37.00 | $555,000.00 | 51,900 | |
| 12/29/2015 | Jason A. Napolitano | CFO | Sell | 3,700 | $40.03 | $148,111.00 | 66,900 | |
| 12/3/2015 | Kevin S Wilson | CEO | Sell | 6,000 | $35.50 | $213,000.00 | 230,000 | |
| 11/25/2015 | Michael J. Mcginley | insider | Sell | 958 | $33.62 | $32,207.96 | 15,928 | |
| 11/24/2015 | Michael J. Mcginley | insider | Sell | 1,427 | $33.33 | $47,561.91 | 15,928 | |
| 9/11/2015 | Jason A Napolitano | CFO | Sell | 1,699 | $33.51 | $56,933.49 | 58,100 | |
| 8/31/2015 | Jason A. Napolitano | CFO | Sell | 4,998 | $33.59 | $167,882.82 | 59,799 | |
| 8/31/2015 | Robert B. Grieve | insider | Sell | 11,098 | $33.77 | $374,779.46 | 101,690 | |
| 8/27/2015 | Robert B. Grieve | insider | Sell | 3,604 | $33.79 | $121,779.16 | 101,690 | |
| 8/17/2015 | Kevin S Wilson | CEO | Sell | 2,498 | $34.90 | $87,180.20 | | |
| 8/17/2015 | Robert B Grieve | Insider | Sell | 8,033 | $34.91 | $280,432.03 | | |
| 8/14/2015 | Kevin S Wilson | CEO | Sell | 2,101 | $34.90 | $73,324.90 | | |
| 8/14/2015 | Rod Lippincott | EVP | Sell | 3,898 | $34.19 | $133,272.62 | | |
| 7/13/2015 | Robert B Grieve | Insider | Sell | 1,000 | $29.99 | $29,990.00 | | |
| 6/8/2015 | Kevin S Wilson | CEO | Sell | 11,810 | $30.08 | $355,244.80 | | |
| 6/3/2015 | Robert B Grieve | Insider | Sell | 17,000 | $31.36 | $533,120.00 | | |
| 6/1/2015 | Jason A Napolitano | CFO | Sell | 7,536 | $32.26 | $243,111.36 | | |
| 5/22/2015 | Steven M Eyl | EVP | Sell | 5,981 | $30.19 | $180,566.39 | | |
| 4/24/2015 | Robert B Grieve | Insider | Sell | 6,000 | $29.67 | $178,020.00 | | |
| 4/13/2015 | Robert B Grieve | Insider | Sell | 4,000 | $26.54 | $106,160.00 | | |
| 3/9/2015 | Jason A Napolitano | CFO | Sell | 5,765 | $26.02 | $150,005.30 | | |
| 3/9/2015 | Kevin S Wilson | CEO | Sell | 10,000 | $25.38 | $253,800.00 | | |
| 3/9/2015 | Robert B Grieve | Insider | Sell | 2,000 | $25.26 | $50,520.00 | | |
| 11/30/2014 | David E Sveen | Director | Buy | 21,428 | $14.00 | $299,992.00 | | |
| 11/30/2014 | Kevin S Wilson | CEO | Sell | 28,928 | $14.00 | $404,992.00 | | |
| 11/21/2014 | Robert B Grieve | Insider | Sell | 6,500 | $15.25 | $99,125.00 | | |
| 11/3/2014 | William A Aylesworth | Director | Sell | 5,000 | $13.67 | $68,350.00 | | |
| 8/4/2014 | Robert B Grieve | Director | Sell | 12,000 | $13.57 | $162,840.00 | | |
| 5/14/2014 | William Aylesworth | Director | Sell | 4,200 | $10.89 | $45,738.00 | 29,797 | |
| 3/31/2014 | Carol Wrenn | Director | Buy | 1,000 | $10.50 | $10,500.00 | 4,000 | |
| 3/31/2014 | Robert Grieve | CEO | Sell | 7,000 | $10.50 | $73,500.00 | 143 | |
| 3/1/2013 | William A Aylesworth | Director | Buy | 2,000 | $8.34 | $16,680.00 | | |
| 10/3/2012 | Master Fund L.P. Cmc | Major Shareholder | Sell | 11,002 | $9.54 | $104,959.08 | | |
| 8/28/2012 | William A Aylesworth | Director | Buy | 2,000 | $7.95 | $15,900.00 | | |
(Data available from 1/1/2013 forward)
Heska (NASDAQ HSKA) News Headlines
| Source: |
|
Heska (NASDAQ:HSKA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Heska (NASDAQ:HSKA) Income Statement, Balance Sheet and Cash Flow Statement
Heska (NASDAQ HSKA) Stock Chart for Thursday, April, 19, 2018
Loading chart…
